Omada Health
NASDAQ:OMDAMedical - Healthcare Information Services
+$0.13 today
- Market cap
- $817.04M
- Beta
- 2.09
- P/E (TTM)
- -162.6
- EPS (TTM)
- -$0.11
Volume 1.68M
Average 1.07M
OMDA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Omada HealthNASDAQ: OMDA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $78.05M rose 42.0% year over year, behind the +49.4% change in trailing-twelve-month revenue. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +42.9% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $344.52M (+32.4%) for the fiscal year ending Dec 2026, a slowdown from the +53.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $78.05M+2.9% QoQ
- Last fiscal yearDec 2025
- $260.21M+53.2% YoY
- LTMMar 2026
- $283.3M+49.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.0% | +30.4% | -11.6 pp |
| 1 year | +53.2% | +32.4% | -20.8 pp |
| 3-year CAGR | +42.9% | +23.3% | -19.6 pp |
| 5-year CAGR | +18.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 260.21M USD
- Year-over-year change
- +53.2%
- 3-year CAGR
- +42.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 260.21M | +53.2% |
| FY2024 | 2024-12-31 | 169.8M | +38.3% |
| FY2023 | 2023-12-31 | 122.78M | +37.7% |
| FY2022 | 2022-12-31 | 89.19M | — |
Revenue vs competitors
How OMDA compares with its peers on the latest reported figures
- OMDA's LTM Mar 2026 revenue of $283.3M is the 4th highest of the 5 companies compared; the peer median is $1.62B.
- Its year-over-year change of +49.4% is the 2nd highest of 5, against a peer median of +14.1%.
- Over three fiscal years its annual growth of +42.9% compares with a peer median of +1.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $2.87B | +29.8% | +64.5% | |
| LTM Mar 2026 | $2.51B | -1.5% | +1.7% | |
| LTM Jun 2026 | $720.06M | +49.8% | — | |
| LTM Mar 2026 | $283.3M | +49.4% | +42.9% | |
| LTM Mar 2026 | $237.38M | -9.3% | -3.5% | |
| Peer median (excluding OMDA) | $1.62B | +14.1% | +1.7% | |
Competitors are the stored peer set for OMDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 89.19M | 122.78M | 169.8M | 260.21M |
| Cost of Revenue | 46.39M | 52.81M | 66.92M | 89.27M |
| Gross Profit | 42.79M | 69.97M | 102.88M | 170.94M |
| Gross Margin | 48.0% | 57.0% | 60.6% | 65.7% |
| Research & Development | 26.17M | 33.74M | 35.92M | 40.68M |
| Selling, General & Admin | 88.97M | 102.23M | 110.61M | 142.23M |
| Operating Expenses | 115.14M | 135.97M | 146.53M | 182.91M |
| Depreciation & Amortization | 4.33M | 4.45M | 4.8M | 5.49M |
| EBITDA | (63.99M) | (58.36M) | (37.83M) | (4.75M) |
| EBITDA Margin | -71.7% | -47.5% | -22.3% | -1.8% |
| Operating Income | (72.35M) | (66M) | (43.65M) | (11.97M) |
| Operating Margin | -81.1% | -53.8% | -25.7% | -4.6% |
| Interest Income | 2.2M | 5.78M | 805K | 5.31M |
| Interest Expense | 4.2M | 4.71M | 4.51M | 2.53M |
| Other Income / Expenses | (168K) | (1.51M) | (3.48M) | (806K) |
| Income Before Tax | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Pre-Tax Margin | -81.3% | -55.0% | -27.8% | -4.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (72.52M) | (67.51M) | (47.14M) | (12.78M) |
| Net Margin | -81.3% | -55.0% | -27.8% | -4.9% |
| EPS (Basic) | (1.30) | (1.21) | (0.85) | (0.22) |
| EPS (Diluted) | (1.30) | (1.21) | (0.85) | (0.22) |
| Weighted Avg Shares | 55.74M | 55.74M | 55.74M | 58.43M |
| Weighted Avg Shares (Diluted) | 55.74M | 55.74M | 55.74M | 58.43M |
Omada Health
NASDAQ:OMDA
Intrinsic Alpha fair value
Locked
Current Price
$13.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.